Artgen Biotech PJSC (MOEX:ISKJ)

Market Cap	4.29B
Revenue (ttm)	1.62B +8.2%
Net Income	246.93M +12.2%
EPS	2.66 -10.6%
Shares Out	71.99M
PE Ratio	22.41
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	261,910
Average Volume	234,009
Open	59.30
Previous Close	58.70
Day's Range	59.12 - 61.82
52-Week Range	36.83 - 177.00
Beta	0.01
RSI	40.78
Earnings Date	Feb 13, 2026

About Artgen Biotech PJSC

Artgen Biotech PJSC, a biotech company, engages in the development of healthcare products in Russia. It develops Betuvax-CoV-2, a vaccine for SARS-COV-2; Tetraflubet, a Flu vaccination; Combi 5V, a Flu + COVID-19 booster vaccine; Betusphere for Immunomodulator; RBT-402, a HPV vaccine; and RBT-501, a vaccine for natural allergy. The company also offers Histograft, a Gene-activated material used as an osteoplastic material, as well as biobanking, genetic research, and regenerative medicine services. In addition, it develops various medical produc...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Country: Russia
• Stock Exchange: Moscow Stock Exchange
• Ticker Symbol: ISKJ

Financial Performance

In 2024, Artgen Biotech PJSC's revenue was 1.52 billion, an increase of 11.18% compared to the previous year's 1.37 billion. Earnings were 214.91 million, an increase of 27.27%.